deferiprone has been researched along with Anemia, Hemolytic in 3 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Anemia, Hemolytic: A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data on the use of deferiprone in young children with iron overload are limited." | 7.83 | Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience. ( Chuansumrit, A; Kadegasem, P; Sasanakul, W; Sirachainan, N; Songdej, D; Wongwerawattanakoon, P, 2016) |
| "Weekly monitoring of absolute neutrophil count (ANC) under deferiprone therapy in thalassemia patients is recommended to avoid agranulocytosis adverse event." | 7.83 | Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. ( Belen, BF; Özsevik, SN; Polat, M; Soylu, E, 2016) |
| "Data on the use of deferiprone in young children with iron overload are limited." | 3.83 | Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience. ( Chuansumrit, A; Kadegasem, P; Sasanakul, W; Sirachainan, N; Songdej, D; Wongwerawattanakoon, P, 2016) |
| "Weekly monitoring of absolute neutrophil count (ANC) under deferiprone therapy in thalassemia patients is recommended to avoid agranulocytosis adverse event." | 3.83 | Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. ( Belen, BF; Özsevik, SN; Polat, M; Soylu, E, 2016) |
| "Treatment with deferiprone of UROS-deficient erythroid cell lines and peripheral blood CD34+-derived erythroid cultures from a patient with CEP inhibited iron-dependent protein ALAS2 and iron-responsive element-binding protein 2 expression and reduced porphyrin production." | 1.56 | Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria. ( Bedel, A; Blouin, JM; Costet, P; Daher, R; Ged, C; Gouya, L; Karim, Z; Lalanne, M; Lamrissi-Garcia, I; Moreau-Gaudry, F; Morice-Picard, F; Puy, H; Richard, E, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Blouin, JM | 1 |
| Ged, C | 1 |
| Lalanne, M | 1 |
| Lamrissi-Garcia, I | 1 |
| Morice-Picard, F | 1 |
| Costet, P | 1 |
| Daher, R | 1 |
| Moreau-Gaudry, F | 1 |
| Bedel, A | 1 |
| Puy, H | 1 |
| Gouya, L | 1 |
| Karim, Z | 1 |
| Richard, E | 1 |
| Chuansumrit, A | 1 |
| Songdej, D | 1 |
| Sirachainan, N | 1 |
| Wongwerawattanakoon, P | 1 |
| Kadegasem, P | 1 |
| Sasanakul, W | 1 |
| Belen, BF | 1 |
| Polat, M | 1 |
| Özsevik, SN | 1 |
| Soylu, E | 1 |
3 other studies available for deferiprone and Anemia, Hemolytic
| Article | Year |
|---|---|
Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
Topics: 5-Aminolevulinate Synthetase; Adult; Anemia, Hemolytic; Animals; Cell Line; Cell Line, Tumor; CRISPR | 2020 |
Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.
Topics: Anemia, Hemolytic; Child; Child, Preschool; Deferiprone; Female; Ferritins; Humans; Iron Chelating A | 2016 |
Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy.
Topics: Adolescent; Anemia, Aplastic; Anemia, Hemolytic; Blood Transfusion; Bone Marrow Diseases; Bone Marro | 2016 |